Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLC
Recruiting
N/A
Interventional Study
Lung Neoplasms
Lymph Node Excision
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 1,362 (estimated)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Lung cancer is the leading cause of cancer related death worldwide. Lobectomy or sub-lobectomy with mediastinal lymph node dissection is the standard surgery. About 50% lung nodules are pure ground-glass or part-solid nodules. Non-solid nodules rarely develop mediastinal lymph node metastasis. The present study is a prospective, multicenter and randomized clinical trial, comparing the overall surv…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Thin-slice HRCT shows single GGN with C/T ≤ 0.5 and no lymph node metastasis;
* Clinical stage IA NSCLC (TNM 8th classification) diagnosed prior or in surgery;
* No history of malignancies within past 5 years or lung surgery;
* No anti-cancer treatment prior to surgery.
Exclu…
Contacts